Schizophrenia Bulletin Advance Access published online on February 16, 2005
Schizophrenia Bulletin, doi:10.1093/schbul/sbi006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* To whom correspondence should be addressed. Models of the neuronal mediation of psychotic symptoms traditionally have focused on aberrations in the regulation of mesolimbic dopaminergic neurons, via their telencephalic afferent connections, and on the impact of abnormal mesolimbic activity for functions of the ventral striatum and its pallidal-thalamic-cortical efferent circuitry. Repeated psychostimulant exposure models major aspects of the sensitized activity of ventral striatal dopaminergic transmission that is observed in patients exhibiting psychotic symptoms. Based on neuroanatomical, neurochemical, and behavioral data, the hypothesis that an abnormally reactive cortical cholinergic input system represents a necessary correlate of a sensitized mesolimbic dopaminergic system is discussed. Moreover, the abnormal cognitive mechanisms that contribute to the development of psychotic symptoms are attributed specifically to the aberrations in cortical cholinergic transmission and to its consequences on the top-down regulation of sensory and sensory-associational input functions. Experimental evidence from studies demonstrating repeated amphetamine-induced sensitization of cortical cholinergic transmission and the ability of antipsychotic drugs to normalize the activity of cortical cholinergic inputs, and from experiments indicating the attentional consequences of manipulations that increase the excitability of cortical cholinergic inputs, supports this hypothesis. Relevant human neuropathological and psychopharmacological data are discussed, and the implications of an abnormally regulated cortical cholinergic input system for pharmacological treatment strategies are addressed. Given the role of cortical cholinergic inputs in gating cortical information processing, even subtle changes in the regulation of this cortexwide input system that represent a necessary transsynaptic consequence of sensitized mesolimbic dopaminergic transmission profoundly contribute to the neuronal mediation of psychotic symptoms.
Article
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
1 Department of Psychology, University of Michigan, Ann Arbor, MI
2 Department of Neuroscience, The Chicago Medical School, Chicago, IL
3 Department of Psychology, Ohio State University, Columbus, OH
Martin Sarter, E-mail: msarter{at}umich.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. H. Nuechterlein, S. J. Luck, C. Lustig, and M. Sarter CNTRICS Final Task Selection: Control of Attention Schizophr Bull, January 1, 2009; 35(1): 182 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bentley, J. Driver, and R. J. Dolan Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health Brain, February 1, 2008; 131(2): 409 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Salgado, T. Bellay, J. A. Nichols, M. Bose, L. Martinolich, L. Perrotti, and M. Atzori Muscarinic M2 and M1 Receptors Reduce GABA Release by Ca2+ Channel Modulation Through Activation of PI3K/Ca2+-Independent and PLC/Ca2+-Dependent PKC J Neurophysiol, August 1, 2007; 98(2): 952 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.R. Corlett, G.D. Honey, and P.C. Fletcher From prediction error to psychosis: ketamine as a pharmacological model of delusions J Psychopharmacol, May 1, 2007; 21(3): 238 - 252. [Abstract] [PDF]
|
|
|
|
|
|
A. V. Terry Jr. and S. P. Mahadik Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 961 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamada, D. J. Gerber, Y. Iwayama, T. Ohnishi, H. Ohba, T. Toyota, J. Aruga, Y. Minabe, S. Tonegawa, and T. Yoshikawa From the Cover: Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia PNAS, February 20, 2007; 104(8): 2815 - 2820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Gao Acute Clozapine Suppresses Synchronized Pyramidal Synaptic Network Activity by Increasing Inhibition in the Ferret Prefrontal Cortex J Neurophysiol, February 1, 2007; 97(2): 1196 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Cannon, R. E. Carson, A. C. Nugent, W. C. Eckelman, D. O. Kiesewetter, J. Williams, D. Rollis, M. Drevets, S. Gandhi, G. Solorio, et al. Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder. Arch Gen Psychiatry, July 1, 2006; 63(7): 741 - 747. [Abstract] [Full Text] [PDF]
|
|